Damora Therapeutics, Inc. (NASDAQ: DMRA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
29.87
-0.05-0.17%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 3.15% | Shs Outstand | 61.55M | Perf Week | 3.21% |
| Market Cap | 1.84B | Forward P/E | - | EPS next Y | -2.06 | Insider Trans | -0.01% | Shs Float | 41.22M | Perf Month | -2.79% |
| Enterprise Value | 1.31B | PEG | 0.00 | EPS next Q | - | Inst Own | - | Short Float | 11.37% | Perf Quarter | 19.73% |
| Income | -421.37M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 8.56 | Perf Half Y | 32.21% |
| Sales | 0.00 | P/B | 2.01 | EPS next Y | -6.92% | ROA | -43.91% | Short Interest | 4.69M | Perf YTD | 30.03% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -122.61% | 52W High | 38.26 -21.94% | Perf Year | 780.00% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -46.73% | 52W Low | 2.45 1121.22% | Perf 3Y | -54.93% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 6.46% 7.59% | Perf 5Y | -72.10% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 52.39% | Oper. Margin | 0.00% | ATR (14) | 2.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 22.48 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 54.31 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 22.48 | EPS Q/Q | 67.71% | SMA20 | -0.30% | Beta | 1.44 | Target Price | 43.75 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 13.20% | Rel Volume | 0.34 | Prev Close | 29.92 |
| Employees | 7 | LT Debt/Eq | 0.07 | Earnings | Oct 30 | SMA200 | 23.41% | Avg Volume | 579.31K | Price | 29.87 |
| IPO Date | Oct 29, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -59.89% - | Net Debt/EBITDA | 2.26 | Volume | 197,364 | Change | -0.17% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-30-26 | Reiterated | Wedbush | Outperform | $35 → $40 |
| Jul-26-26 | Initiated | Jefferies | Buy | $50 |
| Jun-11-26 | Initiated | H.C | Buy | $45 |
| May-28-26 | Initiated | Wedbush | Outperform | $35 |
| Apr-23-26 | Initiated | RBC Capital | Outperform | $40 |
Latest News
Aug-05-26
Aug-05-2608:02AM
08:00AM
Aug-03-26
Aug-03-2604:01PM
Jul-30-26
Jul-30-2609:42AM
Jul-27-26
Jul-27-2608:01AM
Jul-21-26
Jul-21-2608:01AM
Jul-17-26
Jul-01-26
Jul-01-2604:01PM
Jun-12-26
Jun-12-2610:07AM
Jun-11-26
Company
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 1 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | -1 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 10 | 10 | 12 | — | — | — | — | — | |
| Research and Development | 201 | 6 | 24 | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 0 | — | — | — | — | — | |
| Operating Income | -211 | -17 | -36 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | -5 | -2 | — | — | — | — | — | |
| Net Income Before Taxes | -210 | -21 | -38 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -210 | -21 | -38 | — | — | — | — | — | |
| Net Income From Continuing Operations | -210 | -21 | -38 | — | — | — | — | — | |
| Net Income | -210 | -21 | -38 | — | — | — | — | — | |
| EPS (Recurring) | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EPS (Diluted) | -152.99 | -18.53 | -36.08 | — | — | — | — | — | |
| EBITDA | -210 | -21 | -38 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 1 | 1 | 1 | — | — | — | — | — | |
| Market Capitalization | 23 | 5 | 18 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Winslow Garrett | General Counsel | Jul 06 '26 | Sale | 29.98 | 245 | 7,345 | 2,289 | Jul 07 |
| Winslow Garrett | General Counsel | Jul 03 '26 | Option Exercise | 0.00 | 680 | 0 | 2,534 | Jul 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.